In women with uterine adenomyosis, bleeding and pain can have a major impact on quality of life. There is clearly widespread demand for effective long-term medical therapies. The objective of …
Endometriosis is a chronic estrogen-dependent condition affecting women of reproductive age and commonly presents with dysmenorrhea, chronic pelvic pain, dyspareunia, and infertility. In a substantial proportion of patients, pain persists …
To evaluate the efficacy of oral gonadotropin-releasing hormone (GnRH) antagonists versus placebo for treatment of endometriosis-associated pain and to compare individual antagonists indirectly for dysmenorrhea and non-menstrual pelvic pain.
Endometriosis is a chronic, estrogen-dependent inflammatory disease affecting about 10% of reproductive-age women. Chronic pelvic pain is its most disabling symptom, and available therapies often show limited long-term efficacy and …
Was the efficacy of linzagolix, observed at 6 months in women with endometriosis-associated pain, maintained when administered for an additional 6 months?
Elagolix, Linzagolix, and Relugolix, as oral gonadotropin-releasing hormone antagonists, have emerged as promising treatments for endometriosis-associated pain.
Kissei Pharmaceutical Expands Linzagolix Reach with Canadian Licensing Deal MSN
Apotex Strengthens Commitment to Women's Health with Exclusive Canadian Rights to "Linzagolix" for Uterine Fibroid Treatment The Malaysian Reserve
Uterine fibroids and endometriosis are among the most common conditions encountered in gynaecological practice. Fibroids affect 30-70% of women, with up to half experiencing symptoms that significantly impair quality of …